Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...

September 13, 2019

Executive Moves

Adamas Pharma names Neil McFarlane as CEO

Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic advisory role...

September 13, 2019

Markets

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

September 13, 2019

Developments

Helius Medical adds new PoNS clinic in Quebec City

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is opening a new PoNS clinic in Quebec City, Canada to be operated by Clinique Cortex. The PoNS device is authorized in Canada for the acute treatment of chronic...

September 13, 2019

Markets

BTIG ups Eidos Therapeutics PT to $56 from $38

BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...

September 13, 2019

Developments

Tocagen fails Phase 3 trial in recurrent brain cancer

Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with...

September 12, 2019

Markets

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

September 12, 2019

Developments

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...

September 12, 2019

Executive Moves

Gritstone Oncology adds biotech veteran, Elaine Jones, to board

Gritstone Oncology (NASDAQ:GRTS) appointed Elaine Jones as a director, replacing Peter Svennilson, founder of the Column Group and co-lead Series A investor in Gritstone. Dr. Jones was most recently VP, worldwide...

September 12, 2019

Markets

WB starts PhaseBio Pharma at OP; risk-adjusted valuation $16

William Blair launched coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with an “outperform” rating and risk-adjusted valuation of $16. The stock closed at $5.04 on Sept. 10. Analyst Matthew Phipps writes that his...

September 11, 2019

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Adamas Pharma names Neil McFarlane as CEO

Roth starts Cellectar Biosciences at buy; PT $11

Helius Medical adds new PoNS clinic in Quebec City

BTIG ups Eidos Therapeutics PT to $56 from $38

Tocagen fails Phase 3 trial in recurrent brain cancer

Analysts up T2 Biosystems price targets

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

Gritstone Oncology adds biotech veteran, Elaine Jones, to board

WB starts PhaseBio Pharma at OP; risk-adjusted valuation $16

Follow Us

Subscribe

General

More

Subscribe